Covid Flu A/B and RSV 4 in 1 Diagnostic Test
Completed
Conditions studied: Influenza A, Influenza B, COVID - 19, RSV
In brief
The goal of this observational study is to evaluate the diagnostic performance of an investigational Flu A/B, COVID-19 and RSV test in patients with signs and symptoms of respiratory infection. The main questions it aims to answer are: 1. What is the sensitivity and specificity of the investigational test compared with an FDA-cleared reference method for detection of Influenza A, Influenza B, , SARS-CoV-2 and respiratory syncytial virus antigen. 2. What is the overall positive and negative percent agreement between the investigational test and the reference method? Participants will: 1. Provide a respiratory specimen (e.g., nasal or nasopharyngeal swab) for testing with the investigational device. 2. Provide an additional specimen for testing with the FDA-cleared reference method.
Key facts
- Study ID
- NCT07308158
- Run by
- iHealth Labs inc
- People needed
- 1119
- Starts
- 2024-11-15
- Expected to finish
- 2025-12-12
- Last updated by the study team
- 2026-01-08
Who can join
Age: 1 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Written informed consent obtained prior to study enrollment.
- Male or female aged six (6) months or older.
- Subject is currently exhibiting two or more symptoms associated with COVID-19, influenza or RSV (such as, but not limited to, fever, chills, cough, shortness of breath or difficulty breathing, fatigue, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting or diarrhea and must present within six (6) days of symptom onset). Subject must still be exhibiting symptoms on the day of sample collection.
You may not qualify if…
- Subject who is 18 years of age (or the state's legal age of majority) or older and does not understand or is not able and willing to sign the study informed consent.
- Subject has had seasonal influenza and/or the SARS-CoV-2 and/or the RSV vaccine within the past 5 days.
- Subject is not able to tolerate sample collection, or is not willing to contribute the required swab samples for testing or complete the study procedures.
- Subject is currently undergoing antiviral treatment such as baloxavir marboxil (trade name Xofluza®), oseltamivir (Tamiflu®), zanamivir (Relenza®), or peramivir (Rapivab®).
- Subjects currently undergoing treatment and/or within the past thirty (30) days with prescription medication to treat novel Coronavirus SARS-CoV-2 infection, which may include but is not limited to Remdesivir (Veklury), Paxlovid, molnupiravir or receiving convalescent plasma therapy for SARS-CoV-2.
- Subjects who have taken Evusheld (tixagevimab/cilgavimab) within the last 90 days.
- Subjects who have had a nasal wash or aspirate as part of their standard of care treatment on day of study visit prior to the study sample collection.
- Subjects who have had recent craniofacial injury or surgery, including to correct deviation of the nasal septum, within the previous six (6) months.
Where it is running
- iHealth Site 006 — Birmingham, Alabama, United States
- iHealth Site 021 — Trussville, Alabama, United States
- iHealth Site 017 — Dublin, California, United States
- iHealth Site 007 — Huntington Park, California, United States
- iHealth Site 026 — Toluca Lake, California, United States
- iHealth Site 011 — DeLand, Florida, United States
- iHealth Site 013 — Doral, Florida, United States
- iHealth Site 004 — Fort Lauderdale, Florida, United States
- iHealth Site 005 — Fort Lauderdale, Florida, United States
- iHealth Site 019 — Palm Springs, Florida, United States
- iHealth Site 014 — Tamarac, Florida, United States
- iHealth Site 009 — Ammon, Idaho, United States
- iHealth Site 027 — Edison, New Jersey, United States
- iHealth Site 015 — Simpsonville, South Carolina, United States
- iHealth Site 016 — Spartanburg, South Carolina, United States
- iHealth Site 020 — Chattanooga, Tennessee, United States
- iHealth Site 003 — Brownsville, Texas, United States
- iHealth Site 002 — Edinburg, Texas, United States
- iHealth Site 018 — El Paso, Texas, United States
- iHealth Site 023 — Mesquite, Texas, United States
- iHealth Site 025 — Morgantown, West Virginia, United States
- iHealth Site 001 — Quebradillas, Puerto Rico
- iHealth Site 022 — San Juan, Puerto Rico
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.